Literature DB >> 12644391

The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat.

Omar M E Abdel-Salam1, Ayman R Baiuomy, Siham M El-Shenawy, Mahmoud S Arbid.   

Abstract

The present study aimed to evaluate the anti-inflammatory effects of pentoxifylline (PTX), a non-specific phosphodiesterase inhibitor in the rat. Acute inflammation was induced by subplantar injection of carrageenan (1%) in the rat hind paw. Results showed that intraperitoneal (i.p.) administration of PTX (36 or 72 mg kg(-1)) 30 min prior to carrageenan reduced the paw oedema response in dose-dependent manner with a maximal effect of 18.9 and 40.1%, respectively, at 2h post-carrageenan (P<0.001 and <0.001 at respective doses). Theophylline given at equimolar doses (29.9 or 45.8 mg kg(-1), i.p.) did not reduce the oedema response. With higher doses of PTX (144-300 mg kg(-1), i.p.) the anti-oedema effect of the drug was more pronounced, but mainly confined to the first 2h following carrageenan injection and decreasing rapidly thereafter. PTX (72 mg kg(-1), i.p.) given 30 min after carrageenan challenge reduced the oedema response by 24.7 and 26.2% at 1 and 2h after dosing (P<0.05 and <0.05, respectively). PTX (36 or 72 mg kg(-1), i.p.) co-administered with indomethacin (5 mg kg(-1), i.p.) 30 min before carrageenan had little modulatory effect on the anti-oedema effect of indomethacin, but the higher dose of PTX (144 mg kg(-1), i.p.) reduced the anti-inflammatory effect of indomethacin by 24% at 4h post-carrageenan. PTX (72 mg kg(-1), i.p.) enhanced the anti-oedema effect of the selective COX-2 inhibitor celecoxib (33 mg kg(-1), i.p.) by 55.1% at 4h post-carrageenan. In contrast, the higher dose of PTX (144 mg kg(-1), i.p.) reduced the anti-oedema effect of celecoxib by 46.8% at 4h post-carrageenan. PTX (36 or 72 mg kg(-1)) enhanced the anti-oedema effect of dexamethasone (0.1 mg kg(-1)) with maximal effect of 76 and 104.8% at 2h post-carrageenan (P<0.01 and <0.01 for respective doses). PTX (0.6 mg per paw) given with carrageenan into the rat hind paw reduced the oedema response with a maximal effect of 33.4% at 1h following carrageenan. PTX (0.6 mg per paw) given in the contralateral hind paw reduced the carrageenan-induced paw oedema for 1h by 32.2%. Thus, PTX, when given at doses comparable to those used in man for treatment of circulatory disorders displayed anti-inflammatory in vivo and enhanced the anti-inflammatory effect of a selective COX-2 inhibitor or dexamethasone. PTX may have therapeutic potential as anti-inflammatory agent either alone or in combination with non-steroidal anti-inflammatory drugs or with steroids. There is also an intriguing possibility for the use of topical preparations for the management of local inflammatory conditions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12644391     DOI: 10.1016/s1043-6618(03)00002-1

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  21 in total

1.  Pentoxifylline promotes recovery of erectile function in a rat model of postprostatectomy erectile dysfunction.

Authors:  Maarten Albersen; Thomas M Fandel; Haiyang Zhang; Lia Banie; Guiting Lin; Dirk De Ridder; Ching-Shwun Lin; Tom F Lue
Journal:  Eur Urol       Date:  2010-10-26       Impact factor: 20.096

2.  Enhancement of the anti-inflammatory and anti-arthritic effects of theophylline by a low dose of a nitric oxide donor or non-specific nitric oxide synthase inhibitor.

Authors:  Adel Gomaa; Mohsen Elshenawy; Noha Afifi; Eman Mohammed; Romany Thabit
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

3.  Diabetic nephropathy: renoprotective effects of pentoxifylline in the PREDIAN trial.

Authors:  Tony He; Mark E Cooper
Journal:  Nat Rev Nephrol       Date:  2014-09-09       Impact factor: 28.314

4.  Evaluation of the protective effect of pentoxifylline on carrageenan-induced chronic non-bacterial prostatitis in rats.

Authors:  Mahboobeh Hajighorbani; Mahmood Ahmadi-Hamedani; Elaheh Shahab; Farzad Hayati; Khatereh Kafshdoozan; Keivan Keramati; Amin Hossein Amini
Journal:  Inflammopharmacology       Date:  2017-03-09       Impact factor: 4.473

5.  The comparative efficacy of tyloxapol versus pentoxifylline against induced acute phase response in an ovine experimental endotoxemia model.

Authors:  Aliasghar Chalmeh; Alireza Rahmani Shahraki; Seyed Mohammad Mehdi Heidari; Khalil Badiei; Mehrdad Pourjafar; Saeed Nazifi; Mohammad Javad Zamiri
Journal:  Inflammopharmacology       Date:  2015-12-31       Impact factor: 4.473

Review 6.  Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis.

Authors:  Mao-Lu Tian; Yan Shen; Zhao-Lin Sun; Yan Zha
Journal:  Int Urol Nephrol       Date:  2015-04-11       Impact factor: 2.370

7.  Pentoxifylline alleviates high-fat diet-induced non-alcoholic steatohepatitis and early atherosclerosis in rats by inhibiting AGE and RAGE expression.

Authors:  Jing Wu; Miao-yun Zhao; Hao Zheng; Hua Zhang; Ying Jiang
Journal:  Acta Pharmacol Sin       Date:  2010-09-13       Impact factor: 6.150

Review 8.  Pentoxifylline for Diabetic Nephropathy: an Important Opportunity to Re-purpose an Old Drug?

Authors:  Shelly Bhanot; David J Leehey
Journal:  Curr Hypertens Rep       Date:  2016-01       Impact factor: 5.369

9.  Optimizing postoperative sexual function after radical prostatectomy.

Authors:  Manuela Tutolo; Alberto Briganti; Nazareno Suardi; Andrea Gallina; Firas Abdollah; Umberto Capitanio; Marco Bianchi; Niccolò Passoni; Alessandro Nini; Nicola Fossati; Patrizio Rigatti; Francesco Montorsi
Journal:  Ther Adv Urol       Date:  2012-12

10.  Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.

Authors:  Juan F Navarro-González; Carmen Mora-Fernández; Mercedes Muros de Fuentes; Jesús Chahin; María L Méndez; Eduardo Gallego; Manuel Macía; Nieves del Castillo; Antonio Rivero; María A Getino; Patricia García; Ana Jarque; Javier García
Journal:  J Am Soc Nephrol       Date:  2014-06-26       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.